Alpha 2.0
Login Register
» Articles » PMID: 39691724

Lymphoma Combined with Lung Cancer: A Case Report

Overview
Journal Respir Med Case Rep
Date 2024 Dec 18
PMID 39691724
Authors
Dandan Zhang
Jianping Liang
Yanhua Lv
Xikun Huang
Weihong Guo
Affiliations
Soon will be listed here.
Abstract

Lymphoma originates from the lymphatic hematopoietic system and is prone to develop second tumors. We reported a case of lymphoma initially manifesting systematic lymphadenopathies and lung space-occupying lymphoma that developed to lung squamous cell carcinoma in 30 months. The diseases once responded satisfactorily to chemotherapy combined with immunotherapy but progressed after 8 months. Following afatinib administration achieved sustained remission and the progression-free survival is 11 months. Rarely does lymphoma combine with lung cancer and more rarely does lung cancer develop in the original focus of pulmonary lymphoma; first-line and secondary treatment remained potent in treating the complexity.

References
1.
Santos E, Hart L . Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib. Onco Targets Ther. 2020; 13:9305-9321. PMC: 7519820. DOI: 10.2147/OTT.S250446. View
2.
Schollkopf C, Rosendahl D, Rostgaard K, Pipper C, Hjalgrim H . Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer. 2007; 121(1):151-6. DOI: 10.1002/ijc.22672. View
3.
Detterbeck F, Boffa D, Kim A, Tanoue L . The Eighth Edition Lung Cancer Stage Classification. Chest. 2016; 151(1):193-203. DOI: 10.1016/j.chest.2016.10.010. View
4.
Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(5):497-530. DOI: 10.6004/jnccn.2022.0025. View
5.
Greene M, Hoover R, Fraumeni Jr J . Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism. J Natl Cancer Inst. 1978; 61(2):337-40. View